Literature DB >> 18571179

Serum amyloid A may potentiate prothrombotic and proinflammatory events in acute coronary syndromes.

Changjie Song1, Ying Shen, Eric Yamen, Kenneth Hsu, Weixing Yan, Paul K Witting, Carolyn L Geczy, S Ben Freedman.   

Abstract

AIMS: Elevated serum amyloid A (SAA) levels, like C-reactive protein (CRP), predict coronary events. Both induce monocyte tissue factor (TF), and peripheral blood mononuclear cells (PBMC) from patients with coronary artery disease (CAD) express higher TF in response to CRP. This study examined SAA induction of TF and tumour necrosis factor-alpha (TNF) in PBMC from patients with CAD and in monocytoid THP-1 cells. METHODS AND
RESULTS: PBMC from 26 males with CAD (15 stable angina, SA, and 11 acute coronary syndromes, ACS) and 14 male controls were stimulated with SAA. SAA promoted up to six-fold increase in TF activity (recalcification assay) on PBMC from patients, associated with elevated TF mRNA and protein. PBMC responded optimally when monocytes were adherent. Unlike CRP, SAA induced TF and TNF in THP-1 cells. SAA-induced TNF was dose-dependently inhibited by HDL. PBMC from patients with ACS expressed more basal TF (257.4+/-46.8 mU/10(6) PBMC vs. 131.0+/-12.5 mU/10(6) PBMC, P=0.003), and greater SAA-induced TF than cells from controls, whereas no difference was found between SA and controls (ACS 2246+/-493, SA 1364+/-206, controls 1091+/-113 mU/10(6) PBMC, with SAA 250 ng/mL, P=0.002 ACS vs. controls across the dose range). Importantly, SAA-induced TNF levels (ELISA) were much higher in patients with ACS than SA or controls (ACS 211+/-41, SA 108+/-16, controls 73+/-11 pg/mL, with SAA 250 ng/mL, P=0.001 ACS vs. controls or P=0.013 ACS vs. SA across the dose range). SAA-induced TF and TNF correlated positively with serum SAA levels in CAD, but not controls.
CONCLUSIONS: SAA is a prothrombotic and proinflammatory mediator in ACS which may contribute to atherogenesis and its complications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18571179     DOI: 10.1016/j.atherosclerosis.2008.04.049

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  16 in total

Review 1.  Role of serum amyloid A in atherosclerosis.

Authors:  Preetha Shridas; Lisa R Tannock
Journal:  Curr Opin Lipidol       Date:  2019-08       Impact factor: 4.776

2.  Serum amyloid A in uremic HDL promotes inflammation.

Authors:  Thomas Weichhart; Chantal Kopecky; Markus Kubicek; Michael Haidinger; Dominik Döller; Karl Katholnig; Cacang Suarna; Philipp Eller; Markus Tölle; Christopher Gerner; Gerhard J Zlabinger; Markus van der Giet; Walter H Hörl; Roland Stocker; Marcus D Säemann
Journal:  J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 10.121

3.  Serum amyloid A3 is pro-atherogenic.

Authors:  Joel C Thompson; Patricia G Wilson; Preetha Shridas; Ailing Ji; Maria de Beer; Frederick C de Beer; Nancy R Webb; Lisa R Tannock
Journal:  Atherosclerosis       Date:  2017-11-17       Impact factor: 5.162

4.  The correlation between the cardio-ankle vascular index (CAVI) and serum amyloid A in asymptomatic Japanese subjects.

Authors:  Kazuhiko Kotani; Toshiyuki Yamada; Michiaki Miyamoto; Kazuomi Kario; Shun Ishibashi; Nobuyuki Taniguchi
Journal:  Heart Vessels       Date:  2011-09-03       Impact factor: 2.037

5.  Expanded network of inflammatory markers of atherogenesis: where are we now?

Authors:  Seyed Hesameddin Abbasi; Mohammad Ali Boroumand
Journal:  Open Cardiovasc Med J       Date:  2010-02-23

6.  Inflammation, a link between obesity and cardiovascular disease.

Authors:  Zhaoxia Wang; Tomohiro Nakayama
Journal:  Mediators Inflamm       Date:  2010-08-05       Impact factor: 4.711

7.  Serum amyloid A3 is a high density lipoprotein-associated acute-phase protein.

Authors:  Lisa R Tannock; Maria C De Beer; Ailing Ji; Preetha Shridas; Victoria P Noffsinger; Laura den Hartigh; Alan Chait; Frederick C De Beer; Nancy R Webb
Journal:  J Lipid Res       Date:  2017-12-15       Impact factor: 5.922

8.  Association between serum amyloid A levels and coronary heart disease: a systematic review and meta-analysis of 26 studies.

Authors:  Jielin Zhou; Yao Lu; Sufang Wang; Keyang Chen
Journal:  Inflamm Res       Date:  2020-02-22       Impact factor: 4.575

9.  S100A12 suppresses pro-inflammatory, but not pro-thrombotic functions of serum amyloid A.

Authors:  Yuen Ming Chung; Jesse Goyette; Nicodemus Tedla; Kenneth Hsu; Carolyn L Geczy
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

Review 10.  Acute phase reactants as novel predictors of cardiovascular disease.

Authors:  M S Ahmed; A B Jadhav; A Hassan; Qing H Meng
Journal:  ISRN Inflamm       Date:  2012-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.